A5045310997- Dialysis and Renal Disease Management
- Renal Diseases and Glomerulopathies
- Renal Transplantation Outcomes and Treatments
- Complement system in diseases
- Chronic Kidney Disease and Diabetes
- Parathyroid Disorders and Treatments
- Renal cell carcinoma treatment
- Blood Pressure and Hypertension Studies
- Erythropoietin and Anemia Treatment
- Magnesium in Health and Disease
- COVID-19 Clinical Research Studies
- Liver Disease and Transplantation
- Metabolism and Genetic Disorders
- Renal and Vascular Pathologies
- Pharmacological Effects and Toxicity Studies
- Hemoglobinopathies and Related Disorders
- Muscle and Compartmental Disorders
- Bone health and osteoporosis research
- Clinical Nutrition and Gastroenterology
- Central Venous Catheters and Hemodialysis
- Long-Term Effects of COVID-19
- Hormonal Regulation and Hypertension
- Acute Kidney Injury Research
- Sperm and Testicular Function
- Organ Transplantation Techniques and Outcomes
Instituto Dr. Jaime Slullitel
2025
Hospital Universitario Nuestra Señora de Candelaria
2015-2024
Complejo Hospitalario Universitario de Santiago
2001-2022
Servicio Gallego de Salud
2020
Complexo Hospitalario Universitario A Coruña
2020
Mario Negri Institute for Pharmacological Research
2005-2006
Universidad de La Laguna
2001
Observatorio de la Inmigración de Tenerife
1999
Centro Sociosanitario Nuestra Señora del Pino
1993
Hospital Clínico San Carlos
1990-1993
El síndrome hemolítico urémico (SHU) es una entidad clínica definida por la tríada anemia hemolítica no inmune, trombocitopenia e insuficiencia renal aguda, en que las lesiones subyacentes están mediadas un proceso de microangiopatía trombótica (MAT) sistémico. Distintas causas pueden desencadenar el MAT caracteriza SHU. En este documento consideramos SHU atípico (SHUa) como subtipo los fenómenos son fundamentalmente consecuencia del daño producido endotelio microvasculatura y otros órganos...
Diabetic kidney disease (DKD) is the leading cause of ESRD. We conducted an open-label, prospective, randomized trial to determine whether pentoxifylline (PTF), which reduces albuminuria, in addition renin-angiotensin system (RAS) blockade, can slow progression renal patients with type 2 diabetes and stages 3–4 CKD. Participants were assigned receive PTF (1200 mg/d) (n=82) or a control group (n=87) for years. All received similar doses RAS inhibitors. At study end, eGFR had decreased by...
Complement dysregulation occurs in thrombotic microangiopathies (TMAs) other than primary atypical haemolytic uraemic syndrome (aHUS). A few of these patients have been reported previously to be successfully treated with eculizumab.We identified 29 so-called secondary aHUS who had received eculizumab at 11 Spanish nephrology centres. Primary outcome was TMA resolution, defined by a normalization platelet count (>150 × 10 9 /L) and haemoglobin, disappearance all the markers microangiopathic...
The long-term clinical evolution of prediabetes and post-transplant diabetes mellitus (PTDM) is unknown. We analysed, in this cohort study, the reversibility, stability progression PTDM 672 patients using repeated oral glucose tolerance tests (OGTTs) for ≤5 years. Most were on tacrolimus, steroids mycophenolate. About half developed either or prediabetes. incidence was 32% bimodal: early (≤3 months) late PTDM. Early reverted 31%; with use OGTTs necessary to detect around Pretransplant...
Haemolytic uraemic syndrome (HUS) is a clinical entity defined as the triad of nonimmune haemolytic anaemia, thrombocytopenia, and acute renal failure, in which underlying lesions are mediated by systemic thrombotic microangiopathy (TMA). Different causes can induce TMA process that characterises HUS. In this document we consider atypical HUS (aHUS) sub-type phenomena consequence endotelial damage microvasculature kidneys other organs due to disregulation activity complement system. recent...
The association between kidney disease and cancer is multifaceted complex. Persons with chronic (CKD) have an increased incidence of cancer, both treatments can cause impaired function. Renal issues in the setting malignancy worsen patient outcomes diminish adequacy anticancer treatments. In addition, oncology treatment landscape changing rapidly, data on tolerability novel therapies patients CKD are often lacking. Caring for has become more specialized interdisciplinary, currently requiring...
En el ámbito académico se reconoce que la atención del estudiante es fundamental para un aprendizaje efectivo, pero muchos enfrentan dificultades mantenerla durante largos períodos de instrucción. Para abordar este desafío, algunos autores proponen implementar pausas activas, son breves actividad física o relajación integrados en horario escolar. La metodología utilizada incluye revisión estudios previos demuestran los estudiantes participan activas regulares presentan mejores niveles y...
Parathyroid hormone (PTH) is a cardinal factor in the pathogenesis of bone disease dialysis population. The spectrum renal osteodystrophy has been reported to have changed during past years, and adynamic emerged as most common disorder these patients. Continuous ambulatory peritoneal (CAPD) considered risk for development this condition, furthermore, lesion associated with state relative hypoparathyroidism (hypo-PTH). Calcium, vitamin D, phosphorus play key role control parathyroid gland...
Chronic kidney disease (CKD), cancer and hematological diseases share areas of reciprocal influence. Cancer can affect the either as glomerular lesions or a result toxic effects medication radiation with acute (thrombotic microangiopathy, injury, interstitial nephropathies among others) chronic processes (worsening CKD after nephrectomy due to renal cancer, fibrosis, hydroelectrolytic disorders). On other hand, patients who require replacement therapy dialysis particularly transplantation...
The observation that some subjects with low PTH had elevated plasma magnesium (Mg) levels prompted us to analyze in 41 patients on maintenance hemodialysis for 44 +/- 36 months, their serum Mg concentrations, and the relationship between levels. mean concentration was 2.4 0.2 mg/dl. Twenty-four out of (58.5%) hypermagnesemia (serum above 2.5 mg/dl). Patients were classified into 3 groups according level: Group A, (below 120 pg/ml); group B, adequate (120-250 C, high (above 250 pg/ml). There...
There is no approved therapy for coronavirus disease 2019 [severe acute respiratory syndrome 2 (SARS-CoV-2) infection], and the number of worldwide deaths on current standard staggering [1].Current aimed at decreasing viral replication, supporting vital functions addressing most damaging consequences such as hyperinflammation (the so-called cytokine storm) thrombosis.The latter two involve use anti-inflammatory therapies heparin, respectively.We suggest that complement-blocking strategies...
Background: Cavernous cerebral malformations can arise because of mutations in the CCM1 , CCM2 or CCM3 genes, and lack Cdc42 has also been reported to induce these mice. However, role (cerebral cavernous malformation 3)-associated kinases cavernoma development is not known, we, therefore, have investigated their process. Methods: We used a combination an vivo approach, using mice genetically modified be deficient CCM3-associated STK24 STK25 (serine/threonine 24 25), vitro model human...